INVESTOR ALERT: Class Action Lawsuit Against Provectus Biopharmaceuticals, Inc. Announced by Glancy Binkow & Goldberg LLP
June 26 2014 - 10:32AM
Business Wire
Glancy Binkow & Goldberg LLP announces that a class action
lawsuit has been filed in the United States District Court for the
Middle District of Tennessee on behalf of a class (the “Class”)
comprising all purchasers of the securities of Provectus
Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (NYSE:PVCT)
between December 17, 2013 and May 22, 2014, inclusive (the “Class
Period”).
Please contact us at (646) 539-8980, or at
shareholders@glancylaw.com to discuss this matter. If you inquire
by email please include your mailing address, telephone number and
number of shares purchased.
Provectus is a development-stage biopharmaceutical company
engaged in developing pharmaceuticals for oncology and dermatology
indications. The Company’s product line includes PV-10, which has
completed a Phase II study for metastatic melanoma and a Phase I
study for breast cancer, and is in various stages of clinical
development for certain other cancer indications. The Complaint
alleges that defendants misrepresented and/or failed to disclose
material adverse facts concerning the status of PV-10 and
preparations for a Phase III study of the drug.
On May 23, 2014, the Company announced that its application for
a designation of PV-10 as “Breakthrough Therapy” was denied by the
Food and Drug Administration. According to the Company, the FDA
denied the designation because the agency’s review indicated that
“the data upon which the Company based its request for designation
of PV-10 as a Breakthrough Therapy for the treatment of patients
with locally advanced cutaneous melanoma was insufficient to
demonstrate substantial improvement over existing therapies.”
If you are a member of the Class described above, you may move
the Court no later than July 28, 2014, to serve as lead plaintiff,
if you meet certain legal requirements. To be a member of the Class
you need not take any action at this time; you may retain counsel
of your choice or take no action and remain an absent member of the
Class. If you wish to learn more about this action, or have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Lesley Portnoy,
Esquire, of Glancy Binkow & Goldberg LLP, 122 E. 42nd Street,
Suite 2920, New York, New York 10168, at (646) 539-8980, by e-mail
to shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email, please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, New York, NYLesley Portnoy,
646-539-8980shareholders@glancylaw.comwww.glancylaw.com
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024